The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in income, its intellectual property lapse created a wave of lower-priced alternatives , significantly diminishing its dominance. While some firms may attempt to capitalize on similar conditions , the